US cancer drug shortages persist, forcing treatment workarounds at major centers

A survey of leading U.S. cancer centers finds ongoing shortages of cancer medications, with a majority reporting the need for workaround strategies and impacts on clinical trials. The shortages continue a multi-year pattern, but the survey quantifies the current scope and operational strain. This matters because sustained drug shortages can degrade treatment outcomes and delay research.